Purchase this article with an account.
K.A. Yates, R.P. Kowalski, E.G. Romanowski, F.S. Mah, Y.J. Gordon; The In Vitro Evaluation of the Ophthalmic Fluoroquinolones Against Bacterial Conjunctivitis Isolates . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2118.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:We determined the in vitro susceptibilities and potencies based on the MICs of recent conjunctivitis isolates against the 3 current ophthalmic fluoroquinolones (FQ) (ciprofloxacin [C], ofloxacin [O], levofloxacin [L]) and the 2 future FQ (gatifloxacin [G], moxifloxacin [M]). Methods: The MICs of 90 bacterial conjunctivitis isolates (8/98 - 9/02) were determined using Etests. The antibiotic susceptibilities were determined using the NCCLS standards. The in vitro susceptibilities and potencies (isolates with the lowest MICs) were compared statistically. Results: QR, QS = Resistant or susceptible to ciprofloxacin and ofloxacin by disc diffusion. Conclusions: The future ophthalmic FQ (G, M) demonstrated increased in vitro potency against Gram-positive pathogens over the current FQ (C, O, L) but no advantage against Gram-negative pathogens. Only 1 FQ (M) demonstrated an increased in vitro susceptibility for 1 pathogen (St. aureus QR) compared to all other FQ. All other susceptibilities were equal. Clinical studies are needed to confirm these in vitro results. Median MIC (µg/ml) View OriginalDownload SlideView OriginalDownload Slide
This PDF is available to Subscribers Only